Kandall S R, Doberczak T M, Mauer K R, Strashun R H, Korts D C
Am J Dis Child. 1983 Apr;137(4):378-82. doi: 10.1001/archpedi.1983.02140300056015.
Paregoric and phenobarbital, administered randomly in 153 passively addicted neonates, initially appeared to control neonatal abstinence signs equally well. However, seven of the 62 phenobarbital-treated newborns had abstinence-associated seizures within the first month of life, while none of 49 paregoric-treated neonates had seizures. Forty-two neonates initially requiring no specific pharmacotherapy for abstinence signs were born to mothers taking less methadone hydrochloride just before delivery. Five of those 42 neonates, however, had seizures within the first 14 days of life. Seizure occurrence could not be predicted from analysis of early abstinence patterns. We consider paregoric to be the treatment of choice for the neonatal abstinence syndrome. Phenobarbital use should be monitored with serum drug levels and modification of recommended dosage regimens considered.
在153名被动成瘾的新生儿中随机给予阿片酊和苯巴比妥,最初二者似乎对控制新生儿戒断症状的效果相当。然而,62名接受苯巴比妥治疗的新生儿中有7名在出生后的第一个月内出现了与戒断相关的惊厥,而49名接受阿片酊治疗的新生儿中无一例出现惊厥。42名最初不需要针对戒断症状进行特殊药物治疗的新生儿,其母亲在分娩前服用的盐酸美沙酮较少。然而,这42名新生儿中有5名在出生后的前14天内出现了惊厥。通过对早期戒断模式的分析无法预测惊厥的发生。我们认为阿片酊是新生儿戒断综合征的首选治疗药物。使用苯巴比妥时应监测血清药物水平,并考虑调整推荐的给药方案。